Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study

Filippo de Marinis, Tae Min Kim, L. Bonanno, S. Cheng, S-W Kim, Marcello Tiseo, Quincy S. Chu, C. Proto, Adrian G. Sacher, Y.-H. Luo, S. Novello, Dapeng Hao, Christina S. Baik, Lyudmila Bazhenova, J.S. Lee, Byoung Chul Cho, J. Cadranel, Tuan Bao Diep, G. Metro, P R Narayanan, Yasuto Yoneshima, Javier de Castro, Clarissa Baldotto, Christa Haugaard Nyhus, J.C.-H. Yang, Lecia V. Sequist, Benjamin Levy, R. Hartmaier, I. Igwegbe, L. Poole, Wei Xu, M-J. Ahn